We are delighted that our business development team has been recognised with the prestigious Collaboration Deal of the Year Award by the Pharmaceutical Licensing Group for our shared-risk collaboration with Sosei Heptares, an international biopharmaceutical group.
The collaboration set a novel drug discovery programme against a challenging G protein-coupled receptor (GPCR) target, which is associated with neurological disease. The partnership connects Sosei Heptares’ world-leading GPCR-targeted StaR® technology with PharmEnable’s access to novel drug-like chemical space, and combines advanced medicinal chemistry expertise and cutting-edge AI/computational methods.
To learn more about the collaboration, James Dale, Director of Drug Discovery, and Matt Barnes, VP of Drug Discovery at Sosei Heptares chat about the programme as they celebrated completion of the first milestone.
